Amgen, Sandoz Duel Over En Banc Bids In Biosimilars Fight
By Matthew Bultman ( September 9, 2015, 8:12 PM EDT) -- Amgen Inc. and Sandoz Inc. separately asked the full Federal Circuit on Tuesday to reject the other's challenge to a fractured panel decision on key elements of the Affordable Care Act's approval pathway for biosimilars....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.